Actively Recruiting
Evaluating JX10 to Improve Outcomes in Acute Ischemic Stroke A Multicenter, Double-Blind, Placebo-Controlled, Randomized Study for Late Presentations
Led by Corxel Pharmaceuticals · Updated on 2026-09-21
740
Participants Needed
104
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of JX10, a thrombolytic drug, compared to a placebo in adults aged 18 to 90 who have experienced an Acute Ischemic Stroke AIS and present for care between 4.5 to 24 hours after stroke onset. The study aims to determine whether JX10 improves functional outcomes measured by the modified Rankin Scale and assess the risk of symptomatic intracranial hemorrhage associated with the treatment. The study has two parts. In Part 1, participants are randomly assigned to receive either JX10 at two different doses 1 mgkg or 3 mgkg or a placebo. In Part 2, participants receive either the optimal dose of JX10 selected from Part 1 or placebo. The study is double-blind and randomized to ensure unbiased results. Participants will be monitored for functional recovery over 90 days, with the primary outcome being the proportion of participants with no or minimal symptoms at 90 days post-treatment. Safety is tracked by recording incidence of symptomatic intracranial hemorrhage within 36 hours after randomization and adverse events throughout the study. Secondary measures include functional independence, ordinal Rankin scores, and incidence of major bleeding. The total duration of participation spans at least 90 days following treatment.
CONDITIONS
Brief Title
Optimizing Reperfusion to Improve Outcomes and Neurologic Function
Research Team
C
Corxel Pharmaceuticals Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here